Dr Miloš Petrović

internista

Dr Miloš Petrović

Obrazovanje:

  • 1998 diplomirao na Medicinskom fakultetu u Beogradu sa prosekom 9.94
  • 1999 položen stručni ispit za doktora medicine, Ministarstvo zdravlja Republike Srbije
  • 2002 odbrana magistarska teza, kardiovaskularna farmakologija, Medicinski fakultet, Beograd
  • 2005 odbranjena doktorska disertacija, neuronauke, Prvi medicinski fakultet, Karlov univerzitet, Prag, Češka Republika
  • 2007 položen specijalistički ispit iz interne medicine sa odličnom ocenom, Medicinski fakultet, Beograd

Radno iskustvo:

  • 1999 Asistent-pripravnik, Medicinski fakultet, Univerzitet u Beogradu
  • 2006 Asistent, Medicinski fakultet, Univerzitet u Beogradu
  • 2011 Research Fellow, Medical Research Council Centre for Synaptic Plasticity, Bristol University, UK
  • 2012 Docent, Medicinski fakultet Univerziteta u Beogradu
  • 2012-2014 FP7 EU Marie Curie Career Integration Grant Fellow, Centro de Investigación Médica Aplicada (CIMA), Univerzitet u Navari, Pamplona, Španija
  • 2014-2017 Reader in Neuroscience (ekvivalent vanrednog profesora), School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, UK
  • 2017-2019 Medical Advisor, Imunologija, Sanofi, UK
  • 2019 Safety Officer (Farmakovigilanca), Oncology, Sanofi, UK Global
  • 2020 Clinical Research Director, Retke bolesti, Sanofi, UK
  • 2022 Retke bolesti, CSL Vifor, UK & Ireland Medical lead UK & Ireland
  • 2022 KBC Dragiša Mišović – Dedinje, Beograd
  • 2023 Načelnik odeljenja za prijem i zbrinjavanje urgentnih stanja, KBC Dragiša Mišović – Dedinje, Beograd

Publikacije:

1.  Gajic I, Kekic D, Jankovic M, Tomic N, Skoric M, Petrovic M, Mitic Culafic D, Opavski N, Ristivojevic P, Krstic Ristivojevic M, Lukovic B. Nature’s Arsenal: Uncovering Antibacterial Agents Against Antimicrobial Resistance. Antibiotics, 2025. (accepted for publication), https://doi.org/10.3390/antibiotics14030253
2. Gajic I, Tomic N, Lukovic B, Jovicevic M, Kekic D, Petrovic M, Jankovic M, Trudic A, Mitic Culafic D, Milenkovic M, Opavski N. A comprehensive overview on antibacterial agents for combating multidrug-resistant bacteria: the current landscape, development, future opportunities, and challenges. Antibiotics, 2025 (accepted for publication), https://doi.org/10.3390/antibiotics14030221
3. McPherson T., Cork M.J., Goodhead C., Michaelis L.J., Flohr C., Petrovic M., Hennessy L., Rajkovic I., Hudson R. A real-world retrospective observational study exploring NHS resource use in England for the management of moderate-to-severe atopic dermatitis in secondary care for children and adolescents. Pediatric Dermatology. 2023;40(1):50-63.
4. Hudson R.D.A., Ameen M., George S.M.C., Harwood C.A., Weller R.B., Lear J.T., Rout R., Surendranathan T., Petrovic M., Bewley A.P. A Real-World Data Study on the Healthcare Resource Use for Uncontrolled Moderate-to Severe Atopic Dermatitis in Secondary Care in the United Kingdom Prior to the Introduction of Biologic Treatment. Clinico Economics and Outcomes Research. 2022;14:167-177.
5. Petrovic MM*, Viana da Silva S, Clement JP, Vyklicky L, Mulle C, González-González IM*, Henley JM*. Metabotropic action of postsynaptic kainate receptors triggers hippocampal long-term potentiation, Nature Neuroscience, 2017 Apr;20(4):529-539. *co-corresponding authors
6. Marco S*, Giralt A*, Petrovic MMǂ, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, Alberch J,Wesseling JF, Pérez-Otaño I. (2013). Reversing aberrant GluN3A expression rescues synapse loss and motor and cognitive dysfunction in HD mouse models, Nature Medicine, 2013 Jul 14. doi: 10.1038/nm.3246., *equal contribution, ǂ second author
7. Buchanan KA*, Petrovic MM*, Chamberlain SEL, Marrion NV, Mellor JR. (2010). Facilitation of Long-Term Potentiation by Muscarinic M1 Receptors in the Hippocampus is mediated by inhibition of SK channels. Neuron 68(5):948-963, *equal contribution
8. Petrovic M, Sedlacek M, Horak M, Chodounska H, Ladislav Vyklicky Jr. (2005). 20-oxo-5β-pregnan-3α- ylsulfate is a use-dependent NMDA receptor inhibitor. Journal of Neuroscience. 25(37):8439–8450. This paper was awarded by Czech Neuroscience Society.
9. Lukic J, Ilic S, Zivic R, Mitic S, Savic P, Vukomanovic V and Petrovic M.  Case Report: Adrenal collision tumor composed of oncocytoma pheochromocytoma. Frontiers in Oncology. 15:1554355. doi: 10.3389/fonc.2025.1554355. Accepted for publication.  IF=3.3

Internisti